Drug management of pneumonia
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
"Pneumonia"[MeSH Terms] AND "Anti-Bacterial Agents"[MeSH Terms]
Searching the Web
2025 adult community acquired pneumonia antibiotic treatment guideline ATS IDSA outpatient inpatient
Reading File
Reading File
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC6812437
Drug management of pneumonia
Treatment depends on the type of pneumonia, severity, patient age, allergies, kidney function, recent antibiotic exposure, and risk of resistant organisms. This is an adult community-acquired pneumonia (CAP) overview. It is not a substitute for a clinician assessing oxygen level, chest imaging, and severity.
1. Community-acquired pneumonia in adults
| Clinical setting | Usual empiric drug options |
|---|---|
| Outpatient, no important comorbidity | Amoxicillin 1 g orally three times daily, or doxycycline 100 mg orally twice daily. A macrolide such as azithromycin may be used only where pneumococcal macrolide resistance is low. |
| Outpatient with comorbidity such as chronic heart/lung/liver/kidney disease, diabetes, alcoholism, cancer, or asplenia | Amoxicillin-clavulanate or an oral cephalosporin such as cefpodoxime or cefuroxime, plus azithromycin, clarithromycin, or doxycycline. Alternative: respiratory fluoroquinolone monotherapy such as levofloxacin or moxifloxacin, usually reserved when appropriate because of adverse effects. |
| Inpatient, non-severe CAP | An IV beta-lactam such as ceftriaxone, cefotaxime, ampicillin-sulbactam, or ceftaroline, plus azithromycin. Alternative: the beta-lactam plus doxycycline, or respiratory fluoroquinolone monotherapy when indicated. |
| Inpatient, severe CAP / ICU | IV beta-lactam plus azithromycin is commonly preferred. A beta-lactam plus a respiratory fluoroquinolone is another option. Obtain cultures and tailor treatment quickly. |
These regimens cover common bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms including Mycoplasma, Chlamydia pneumoniae, and Legionella. The Washington Manual notes that atypical bacterial causes cannot reliably be distinguished clinically, so empiric therapy usually includes appropriate coverage based on severity and setting. The Washington Manual of Medical Therapeutics, p. 541.
2. When to add resistant-organism coverage
Do not add MRSA or Pseudomonas aeruginosa drugs routinely. Add them only with validated risk factors, such as prior respiratory isolation or recent hospitalization with IV antibiotics, while using local microbiology data.
- Suspected MRSA pneumonia: add vancomycin or linezolid.
- Suspected Pseudomonas pneumonia: use an antipseudomonal beta-lactam such as piperacillin-tazobactam, cefepime, ceftazidime, meropenem, or imipenem, combined with other treatment as needed.
- De-escalate or stop broad coverage once cultures and clinical data exclude these pathogens. The 2019 ATS/IDSA guideline recommends moving away from the old broad “healthcare-associated pneumonia” category and instead using local epidemiology plus validated individual risk factors, as summarized in the ATS/IDSA CAP guideline.
3. Viral pneumonia
- Influenza pneumonia: give oseltamivir promptly, including in hospitalized patients even if symptoms began more than 48 hours earlier.
- COVID-19 pneumonia: management is severity-specific and may include antiviral treatment early in high-risk outpatients, and oxygen-directed inpatient care. Antibiotics are not automatically indicated unless bacterial co-infection is suspected.
- For otherwise healthy outpatients with confirmed viral CAP, the 2025 ATS guidance suggests antibiotics may be withheld in selected cases. See the ATS 2025 update.
4. Aspiration pneumonia
Treat as bacterial CAP in most cases. Routine extra anaerobic coverage is generally not needed unless there is lung abscess, empyema, or a classic high-risk anaerobic syndrome. Ampicillin-sulbactam inpatient or amoxicillin-clavulanate outpatient are common choices when aspiration-related bacterial infection is likely.
Do not confuse aspiration pneumonia with aspiration pneumonitis, a chemical injury after gastric aspiration. Pneumonitis often needs supportive treatment rather than immediate antibiotics unless bacterial infection develops. Goldman-Cecil Medicine, p. 1002.
5. Duration and switching therapy
- Reassess after 48 to 72 hours.
- Use culture/PCR results to narrow therapy.
- Switch IV to oral antibiotics once the person is improving, can take oral drugs, and is hemodynamically stable.
- Traditionally, treatment continues until clinical stability and for at least 5 days. The 2025 ATS update allows a shorter course, at least 3 days, for stable selected adult outpatients, although evidence certainty is low. Complicated infection, MRSA/Pseudomonas, abscess, empyema, or slow response usually requires individualized longer treatment.
6. Supportive medications
- Paracetamol (acetaminophen) or ibuprofen, if safe, for fever and pleuritic pain.
- Fluids if dehydrated, but avoid excess fluid in heart or kidney failure.
- Supplemental oxygen for hypoxemia.
- Bronchodilator only if wheeze/bronchospasm or coexisting asthma/COPD.
- Systemic corticosteroids are not routine for non-severe CAP. Current ATS guidance recommends against them in hospitalized non-severe CAP; they may be considered in severe CAP or refractory septic shock under clinician supervision.
Key safety points
- Antibiotics should be selected after considering allergy history, pregnancy, renal/hepatic function, QT-prolonging medications, and local antibiotic resistance.
- Fluoroquinolones can cause serious adverse effects, including tendinopathy, neuropathy, CNS effects, QT prolongation, and C. difficile infection, so they should not be a default choice when safer effective alternatives exist.
- Seek urgent assessment for confusion, blue lips, oxygen saturation below usual or below 92% if no chronic target is prescribed, severe breathlessness, persistent hypotension, chest pain, or inability to drink/take medication.
Recent evidence may refine choices: a 2025 systematic review and network meta-analysis evaluated empiric treatment for moderate-to-severe CAP (PMID 40602496); regimen selection still needs to be individualized to severity and local resistance.
This is a shared conversation. Sign in to Orris to start your own chat.